Tariq Shafi1, Thomas H Hostetter2, Timothy W Meyer3, Seungyoung Hwang4, Xin Hai2, Michal L Melamed5, Tanushree Banerjee6, Josef Coresh7, Neil R Powe6. 1. Department of Medicine, Johns Hopkins University, Baltimore, MD; Welch Center for Prevention, Epidemiology and Clinical Research, Johns Hopkins University, Baltimore, MD. Electronic address: tshafi@jhmi.edu. 2. Department of Medicine, Case Western University School of Medicine, Cleveland, OH. 3. Department of Medicine, Palo Alto Veterans Affairs Health Care System and Stanford University, Palo Alto, CA. 4. Department of Medicine, Johns Hopkins University, Baltimore, MD. 5. Department of Medicine, Albert Einstein College of Medicine, Bronx, NY; Department of Epidemiology and Population Health, Albert Einstein College of Medicine, Bronx, NY. 6. Department of Medicine, University of California, San Francisco, CA. 7. Department of Medicine, Johns Hopkins University, Baltimore, MD; Welch Center for Prevention, Epidemiology and Clinical Research, Johns Hopkins University, Baltimore, MD; Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD; Department of Biostatistics, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD.
Abstract
BACKGROUND: Asymmetric (ADMA) and symmetric dimethylarginine (SDMA) are putative uremic toxins that may exert toxicity by a number of mechanisms, including impaired nitric oxide synthesis and generation of reactive oxygen species. The study goal was to determine the association between these metabolites and cardiovascular outcomes in hemodialysis patients. STUDY DESIGN: Post hoc analysis of the Hemodialysis (HEMO) Study. SETTING & PARTICIPANTS: 1,276 prevalent hemodialysis patients with available samples 3 to 6 months after randomization. PREDICTOR: ADMA and SDMA measured in stored specimens. OUTCOMES: Cardiac death, sudden cardiac death, first cardiovascular event, and any-cause death. Association with predictors analyzed using Cox regression adjusted for potential confounders (including demographics, clinical characteristics, comorbid conditions, albumin level, and residual kidney function). RESULTS:Mean age of patients was 57±14 (SD) years, 63% were black, and 57% were women. Mean ADMA (0.9±0.2μmol/L) and SDMA levels (4.3±1.4μmol/L) were moderately correlated (r=0.418). Higher dialysis dose or longer session length were not associated with lower predialysis ADMA or SDMA concentrations. In fully adjusted models, each doubling of ADMA level was associated with higher risk (HR per 2-fold higher concentration; 95% CI) of cardiac death (1.83; 1.29-2.58), sudden cardiac death (1.79; 1.19-2.69), first cardiovascular event (1.50; 1.20-1.87), and any-cause death (1.44; 1.13-1.83). Compared to the lowest ADMA quintile (<0.745 μmol/L), the highest ADMA quintile (≥1.07μmol/L) was associated with higher risk (HR; 95% CI) of cardiac death (2.10; 1.44-3.05), sudden cardiac death (2.06; 1.46-2.90), first cardiovascular event (1.75; 1.35-2.27), and any-cause death (1.56; 1.21-2.00). SDMA level was associated with higher risk for cardiac death (HR, 1.40; 95% CI, 1.03-1.92), but this was no longer statistically significant after adjusting for ADMA level (HR, 1.20; 95% CI, 0.86-1.68). LIMITATIONS: Single time-point measurement of ADMA and SDMA. CONCLUSIONS: ADMA and, to a lesser extent, SDMA levels are associated with cardiovascular outcomes in hemodialysis patients.
RCT Entities:
BACKGROUND: Asymmetric (ADMA) and symmetric dimethylarginine (SDMA) are putative uremic toxins that may exert toxicity by a number of mechanisms, including impaired nitric oxide synthesis and generation of reactive oxygen species. The study goal was to determine the association between these metabolites and cardiovascular outcomes in hemodialysis patients. STUDY DESIGN: Post hoc analysis of the Hemodialysis (HEMO) Study. SETTING & PARTICIPANTS: 1,276 prevalent hemodialysis patients with available samples 3 to 6 months after randomization. PREDICTOR: ADMA and SDMA measured in stored specimens. OUTCOMES: Cardiac death, sudden cardiac death, first cardiovascular event, and any-cause death. Association with predictors analyzed using Cox regression adjusted for potential confounders (including demographics, clinical characteristics, comorbid conditions, albumin level, and residual kidney function). RESULTS: Mean age of patients was 57±14 (SD) years, 63% were black, and 57% were women. Mean ADMA (0.9±0.2μmol/L) and SDMA levels (4.3±1.4μmol/L) were moderately correlated (r=0.418). Higher dialysis dose or longer session length were not associated with lower predialysis ADMA or SDMA concentrations. In fully adjusted models, each doubling of ADMA level was associated with higher risk (HR per 2-fold higher concentration; 95% CI) of cardiac death (1.83; 1.29-2.58), sudden cardiac death (1.79; 1.19-2.69), first cardiovascular event (1.50; 1.20-1.87), and any-cause death (1.44; 1.13-1.83). Compared to the lowest ADMA quintile (<0.745 μmol/L), the highest ADMA quintile (≥1.07μmol/L) was associated with higher risk (HR; 95% CI) of cardiac death (2.10; 1.44-3.05), sudden cardiac death (2.06; 1.46-2.90), first cardiovascular event (1.75; 1.35-2.27), and any-cause death (1.56; 1.21-2.00). SDMA level was associated with higher risk for cardiac death (HR, 1.40; 95% CI, 1.03-1.92), but this was no longer statistically significant after adjusting for ADMA level (HR, 1.20; 95% CI, 0.86-1.68). LIMITATIONS: Single time-point measurement of ADMA and SDMA. CONCLUSIONS:ADMA and, to a lesser extent, SDMA levels are associated with cardiovascular outcomes in hemodialysis patients.
Authors: Shani Shastri; Navdeep Tangri; Hocine Tighiouart; Gerald J Beck; Panagiotis Vlagopoulos; Daniel Ornt; Garabed Eknoyan; John W Kusek; Charles Herzog; Alfred K Cheung; Mark J Sarnak Journal: Clin J Am Soc Nephrol Date: 2011-11-10 Impact factor: 8.237
Authors: Joe M El-Khoury; Dustin R Bunch; Edmunds Reineks; Raymond Jackson; Roxanne Steinle; Sihe Wang Journal: Anal Bioanal Chem Date: 2011-11-29 Impact factor: 4.142
Authors: C Zoccali; S Bode-Böger; F Mallamaci; F Benedetto; G Tripepi; L Malatino; A Cataliotti; I Bellanuova; I Fermo; J Frölich; R Böger Journal: Lancet Date: 2001 Dec 22-29 Impact factor: 79.321
Authors: Michael V Rocco; Guofen Yan; Jennifer Gassman; Julia Breyer Lewis; Daniel Ornt; Barbara Weiss; Andrew S Levey Journal: Am J Kidney Dis Date: 2002-01 Impact factor: 8.860
Authors: Peter Willeit; Daniel F Freitag; Jari A Laukkanen; Susmita Chowdhury; Reeta Gobin; Manuel Mayr; Emanuele Di Angelantonio; Rajiv Chowdhury Journal: J Am Heart Assoc Date: 2015-05-28 Impact factor: 5.501
Authors: Heidi Borgeraas; Elin Strand; Eva Ringdal Pedersen; Jutta Dierkes; Per Magne Ueland; Reinhard Seifert; Eirik Rebnord Wilberg; Pavol Bohov; Rolf K Berge; Dennis W T Nilsen; Ottar Nygård Journal: Cardiol Res Pract Date: 2012-12-31 Impact factor: 1.866
Authors: Insa E Emrich; Adam M Zawada; Jens Martens-Lobenhoffer; Danilo Fliser; Stefan Wagenpfeil; Gunnar H Heine; Stefanie M Bode-Böger Journal: Clin Res Cardiol Date: 2017-11-03 Impact factor: 5.460
Authors: André Nanny Vieira Le Sueur; Silvano Salgueiro Geraldes; Alessandra Melchert; Regina Kiomi Takahira; Michael Coyne; Rachel Murphy; Donald Szlosek; Priscylla Tatiana Chalfun Guimarães-Okamoto Journal: J Vet Intern Med Date: 2019-09-12 Impact factor: 3.333